New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs NAD+

Livagen vs NAD+

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
Anti-Aging & Longevity
NAD+
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
Half-Life
Short (minutes); gene-regulatory effects are sustained
Varies by route; IV provides direct cellular delivery
Admin Route
SubQ, Oral
IV, SubQ, Oral
Research
Typical Dose
10 mg per day
500–1000 mg
Frequency
Daily for 10–30 days
Daily for 4–10 days (loading), then monthly maintenance
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Restored cellular energy production (ATP)
  • Sirtuin activation for longevity and metabolic regulation
  • Enhanced DNA repair capacity
  • Improved mitochondrial function and biogenesis
  • Cognitive clarity and mental energy
  • Reduced inflammation
  • Addiction withdrawal support (opioids, alcohol, benzodiazepines)
  • Improved sleep quality
  • Enhanced athletic endurance
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Flushing and warmth during IV infusion
  • Nausea during rapid IV administration
  • Chest tightness (from rapid infusion — slow the rate)
  • Injection site irritation (subcutaneous)
  • +1 more
Stacks With